4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000899243-24-000266
Pres., R&D, and CMO sold 73,888 shares at an average $243.92 ($18,022,588)
- Pres., R&D, and CMO acquired 73,888 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Taub Rebecca · Pres., R&D, and CMO
Table I: Non-derivative
22 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-04-03 | Exercise or conversion : show line 1 in the form 10b5-1 | +27,845 | $9.45 | $263,135 | 486,844 | D |
| 2024-04-03 | Sale : show line 2 in the form 10b5-1 | −135 | $242.00 | $32,670 | 486,709 | D |
| 2024-04-03 | Sale : show line 3 in the form 10b5-1 | −2,634 | $243.68 | $641,866 | 484,075 | D |
| 2024-04-03 | Sale : show line 4 in the form 10b5-1 | −4,070 | $244.68 | $995,854 | 480,005 | D |
| 2024-04-03 | Sale : show line 5 in the form 10b5-1 | −18,917 | $245.34 | $4,641,014 | 461,088 | D |
| 2024-04-03 | Sale : show line 6 in the form 10b5-1 | −2,089 | $246.32 | $514,573 | 458,999 | D |
| 2024-04-04 | Exercise or conversion : show line 7 in the form 10b5-1 | +18,537 | $9.45 | $175,175 | 477,536 | D |
| 2024-04-04 | Sale : show line 8 in the form 10b5-1 | −4,200 | $240.88 | $1,011,679 | 473,336 | D |
| Open-market sales · 73,888 sh · avg $243.92 · $18,022,588 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-04-03 | Exercise or conversion : show line 23 in the form 10b5-1 Stock Option (Right to Buy) | −27,845 | 125,283 | D |
| 2024-04-04 | Exercise or conversion : show line 24 in the form 10b5-1 Stock Option (Right to Buy) | −18,537 | 106,746 | D |
| 2024-04-05 | Exercise or conversion : show line 25 in the form 10b5-1 Stock Option (Right to Buy) | −27,506 | 79,240 | D |
Loading xslF345X05/doc4.xml…